In This Article:
Last week, you might have seen that ClearPoint Neuro, Inc. (NASDAQ:CLPT) released its third-quarter result to the market. The early response was not positive, with shares down 9.6% to US$11.65 in the past week. The results were mixed overall, with revenues slightly ahead of analyst estimates at US$8.1m. Statutory losses by contrast were 3.8% larger than predictions at US$0.18 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
See our latest analysis for ClearPoint Neuro
Taking into account the latest results, the current consensus from ClearPoint Neuro's three analysts is for revenues of US$38.8m in 2025. This would reflect a major 27% increase on its revenue over the past 12 months. The loss per share is expected to ameliorate slightly, reducing to US$0.60. Before this latest report, the consensus had been expecting revenues of US$39.0m and US$0.62 per share in losses. It looks like there's been a modest increase in sentiment in the recent updates, with the analysts becoming a bit more optimistic in their predictions for losses per share, even though the revenue numbers were unchanged.
The average price target held steady at US$13.33, seeming to indicate that business is performing in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values ClearPoint Neuro at US$15.00 per share, while the most bearish prices it at US$10.00. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The period to the end of 2025 brings more of the same, according to the analysts, with revenue forecast to display 21% growth on an annualised basis. That is in line with its 20% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 8.3% annually. So although ClearPoint Neuro is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.